Racura Oncology (RAC) Stock Overview
Operates as a Phase 3 clinical biopharmaceutical company for cancer care. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RAC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Racura Oncology Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.24 |
| 52 Week High | AU$4.90 |
| 52 Week Low | AU$0.93 |
| Beta | 0.91 |
| 1 Month Change | -20.57% |
| 3 Month Change | -26.80% |
| 1 Year Change | 85.12% |
| 3 Year Change | 12.85% |
| 5 Year Change | -22.76% |
| Change since IPO | 778.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| RAC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -0.9% | -1.2% | -2.5% |
| 1Y | 85.1% | -34.3% | 1.6% |
Return vs Industry: RAC exceeded the Australian Biotechs industry which returned -34.3% over the past year.
Return vs Market: RAC exceeded the Australian Market which returned 1.5% over the past year.
Price Volatility
| RAC volatility | |
|---|---|
| RAC Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: RAC has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: RAC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Daniel Tillett | www.racuraoncology.com |
Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin.
Racura Oncology Ltd Fundamentals Summary
| RAC fundamental statistics | |
|---|---|
| Market cap | AU$408.41m |
| Earnings (TTM) | -AU$4.79m |
| Revenue (TTM) | AU$6.04m |
Is RAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAC income statement (TTM) | |
|---|---|
| Revenue | AU$6.04m |
| Cost of Revenue | AU$635.21k |
| Gross Profit | AU$5.41m |
| Other Expenses | AU$10.20m |
| Earnings | -AU$4.79m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 89.49% |
| Net Profit Margin | -79.22% |
| Debt/Equity Ratio | 0% |
How did RAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/07 15:02 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Racura Oncology Ltd is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Independent Investment Research (Aust.) Pty Ltd |
| Chris Kallos | MST Financial Services Pty Limited |